Many types of immune cells are involved in the activation and regulation of the immune system attack against tumor cells (APC, LyT, CD4+, etc.), but we focused on specific markers for infiltrating LyTc, NK, and T-regs that have the ability to recognize directly the tumor cells’ neoantigens coupled with major histocompatibility complex 1 (CMH1) and are directly targeting tumor cells. The gene discussed is CD4; the disease is neoplasm.